Regen BioPharma Inc
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation NV
Business Address 4700 SPRING ST #304, LA MESA, CA, 91942
Mailing Address 4700 SPRING ST #304, LA MESA, CA, 91942
Phone 619-722-5505
Fiscal Year End 0930
EIN 455192997
Financial Overview
FY2025
-$668K
Net Income
-$5.10M
Stockholders' Equity
$716
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-Q Quarterly financial report | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 21, 2026 | View on SEC |
| 10-K Annual financial report | December 30, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 8-K Current report of material events | October 3, 2025 | View on SEC |
| 8-K Current report of material events | September 19, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | September 12, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 11, 2025 | View on SEC |
| 8-K Current report of material events | August 7, 2025 | View on SEC |
Annual Reports
10-K December 30, 2025
- Regen BioPharma Inc.'s financial year ends on September 30th.
- The company's capital structure includes common stock and multiple series of preferred stock (Series A, AA, M, NC).
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.